Introducing GEMTESA® (vibegron) 75 mg tablets for the Treatment of Overactive Bladder (OAB) An Overview of OAB Implications and Challenges and a New Treatment Option for Long-Term Care
Supported by Urovant Sciences: This product theater will discuss the clinical profile and prescribing information for GEMTESA® (vibegron) 75mg tablets, for the treatment of Overactive Bladder. The presentation will also review challenges and implications associated with overactive bladder in long term care.
Director of Primary Care,
Credits: None available.
You must be logged in and own this session in order to